Intelligence · Patents
Patents expiring in 2039
Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.
- Patents
- 1,782
Quick answer
1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10351580
Acene-based transmitter molecules for photon upconversion
granted -
US 10351618
UTI fusion proteins
granted -
US 10350312
Magnetic microstructures for magnetic resonance imaging
granted -
US 10350265
Therapeutic applications of Smad7
granted -
US 10351628
Antibody fragments, compositions and uses thereof
granted -
US 10351598
Peptide with anti-obesity and anti-diabetic efficacy and use thereof
granted -
US 10351587
Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate
granted -
US 10350273
Treatment of hormonal disorders of growth
granted -
US 10350228
Treatment of sickle cell disease and inflammatory conditions
granted -
US 10350267
Polypeptide-polymer conjugates and methods of use thereof
granted -
US 10350256
Compositions for the treatment of dermatological conditions, disorders or diseases
granted -
US 10350306
Methods and compositions for treating genetically linked diseases of the eye
granted -
US 10350292
Agonist antibodies that bind human CD137 and uses thereof
granted -
US 10350296
Chewable gelatin formulations
granted -
US 10351522
Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
granted -
US 10351532
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
granted -
US 10351547
Somatostatin modulators and uses thereof
granted -
US 10351589
3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders
granted -
US 10351597
Peptide with anti-obesity and anti-diabetes activity and use thereof
granted -
US 10351606
Mutated Salmonella enterica
granted -
US 10351844
Methods and compositions for treating leber congenital amaurosis
granted -
US 10351878
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10350170
Solid preparation
granted -
US 10350163
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 10350183
Intravenous baclofen formulations and treatment methods
granted -
US 10350193
Super-oxide dismutase mimetics
granted -
US 10350162
Methods and compositions for oral administration of exenatide
granted -
US 10350249
Reduction of milk glycans and their degradation products in the neonate gut
granted -
US 10350239
Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
granted -
CA 3088180
COMPOSITIONS ET METHODES POUR L'EDITION GENIQUE PAR CIBLAGE DE LA TRANSFERRINE
granted -
US 10358419
1,3-dipolar [70]fulleropyrrolidinium iodide derivatives
granted -
US 10357448
Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
granted -
US 10357453
Methods of eye treatment using therapeutic compositions containing dipyridamole
granted -
US 10357460
Particulate comprising a calcium-containing compound and a sugar alcohol
granted -
US 10357217
Method for positron emission tomography (PET) imaging analysis for classifying and diagnosing of neurological diseases
granted -
US 10357465
Eutectic formulations of cyclobenzaprine hydrochloride
granted -
US 10357484
Heterocyclic compound
granted -
US 10357510
Metal nanoclusters and uses thereof
granted -
US 10357522
Bacteriophage compositions and methods of selection of components against specific bacteria
granted -
US 10357539
Use of peptides that block metadherin-SND1 interaction as treatment for cancer
granted -
US 10357477
Anticancer compounds
granted -
US 10357565
Targeting microbubbles
granted -
US 10357464
Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
granted -
US 10358659
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10357554
AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
granted -
US 10358658
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10358433
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
granted -
US 10358439
DNA binding agents with a minor groove binding tail
granted
Frequently asked questions
How many pharma patents expire in 2039?
1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.